Therapeutic compounds and synthesis

Patent metadata

Field	Value
Publication number	US-10040797-B2
Application number	US-201615254960-A
Country	US
Kind code	B2
Filing date	Sep 1, 2016
Priority date	Sep 4, 2015
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The invention provides compounds of Formula 1:

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

First claim

What is claimed is:

1. A compound of Formula 1:

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof.

2. A compound of claim 1 , wherein Formula 1 is:

3. A pharmaceutical composition comprising a compound of claim 2 , and a pharmaceutically acceptable carrier or diluent.

4. A method for treating pain in a subject in need comprising administering to the subject an effective amount of the compound of claim 2 .

5. The method of claim 4 , wherein the compound is administered to effect localized delivery to the subject.

6. The method of claim 4 , wherein the compound is administered to effect systemic delivery to the subject.

7. The method of claim 4 , wherein the pain is neuropathic pain or chronic pain.

8. A method of making a compound of Formula 1:

comprising:
reacting a compound of Formula 2:

with an acid.

9. The method of claim 8 , wherein the acid is trifluoroacetic acid.

10. The method of claim 8 , further comprising:
making the compound of Formula 2 by reacting a compound of Formula 3:

with dimethylaminopyridine (DMAP);
making the compound of Formula 3 by reacting a compound of Formula 4:

with tert-butyldiphenylchlorosilane;
making the compound of Formula 4 by reacting a compound of Formula 5.b:

with 3,3,3-trifluoropropanoic acid;
making the compound of Formula 5.b by chirally separating a compound of Formula 6:

making the compound of Formula 6 by reacting a compound of Formula 7:

with hydrogen in the presence of a catalyst; and
making the compound of Formula 7 by reacting a compound of Formula 8:

with Boc 2 O.

11. The method of claim 10 , wherein:
the making of the compound of Formula 3 further comprises pyridine;
the making of the compound of Formula 4 further comprises N—N-Diisopropylethylamine and/or (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate) sodium triacetoxyborohydride;
the catalyst in the making of the compound of Formula 6 comprises palladium or palladium on carbon; and
the making of the compound of Formula 7 further comprises triethylamine.

12. The method of claim 8 , further comprising:
making the compound of Formula 8 by reacting a compound of Formula 9:

with iodotrimethylsilane;
making the compound of Formula 9 by reacting a compound of Formula 10:

with tert-butyldiphenylchlorosilane;
making the compound of Formula 10 by reacting a compound of Formula 11:

with benzaldehyde;
making the compound of Formula 11 by cyclizing a compound of Formula 11.a:

in a solvent;
making the compound of Formula 11.a by reacting a compound of Formula 12:

with hydrogen in the presence of a catalyst;
making the compound of Formula 12 by reacting a compound of Formula 13:

with potassium cyanide;
making the compound of Formula 13 by reacting a compound of Formula 14:

with mesyl chloride;
making the compound of Formula 14 by reacting a compound of Formula 15:

with a reducing agent;
making the compound of Formula 15 by reacting a compound of Formula 16:

with ethyl chloroformate;
making the compound of Formula 16 by reacting a compound of Formula 17:

with benzoic acid in the presence of an activating agent; and
making the compound of Formula 17 by reacting a compound of Formula 18:

with a reducing agent.

13. The method of claim 12 , wherein:
the making of the compound of Formula 8 takes place at a temperature above 60° C.;
the making of the compound of Formula 9 further comprises imidazole;
the making of the compound of Formula 10 further comprises sodium triacetoxyborohydride;
the solvent in the making of the compound of Formula 11 is ethanol;
the catalyst in the making of the compound of Formula 11.a is Raney-nickel;
the making of the compound of Formula 12 further comprises 18-crown-6;
the making of the compound of Formula 13 further comprises triethylamine;
the reducing agent in the making of the compound of Formula 14 is sodium borohydride;
the making of the compound of Formula 15 further comprises a base;
the activating agent in the making of the compound of Formula 16 is diethylazodicaroxylate with triphenylphosphine or diisopropyl azodicarboxylate with triphenylphosphine; and
the reducing agent in the making of the compound of Formula 17 is sodium borohydride and/or the reaction further comprises HCL in isopropyl alcohol.

14. A compound of Formula 2:

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof.

15. A compound of Formula 3:

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof.

16. A compound of Formula 4:

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof.

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Decorte Bart
• Russcher Jacob Cornelis
• Monnee Menno Cornelis Franciscus

Classifications

• A61P29/02

  without antiinflammatory effect · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• C07D471/18 Primary

  Bridged systems · CPC title